CRSP News and Press, CRISPR Therapeutics AG From 02/15/24

2024-02-15 13:01:01 ET More on CRISPR Therapeutics Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range Crispr...

2024-02-15 11:30:02 ET Wolfe Research analyst issues PEER PERFORM recommendation for CRSP on February 15, 2024 11:36AM ET. CRSP was trading at $83.825 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - B...

ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Vir...

2024-02-14 15:41:42 ET More on CRISPR, Intellia Therapeutics, etc. Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off Vertex, C...

2024-02-13 08:42:36 ET More on CRISPR Therapeutics Vertex, CRISPR gene therapy approved in EU for sickle cell disease, beta-thalassemia CRISPR CMO who resigned after Casgevy approval lands at Takeda Read the full article on Seeking Alpha For further details s...

- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in vivo gene writing programs - ...

2024-02-13 06:05:22 ET Vertex Pharmaceuticals ( NASDAQ: VRTX ) has received conditional marketing authorization from the European Commission for its gene editing therapy, Casgevy (exagamglogene autotemcel), developed with CRISPR Therapeutics ( NASDAQ: CRSP ).... Re...

— Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment — ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transforma...

2024-02-11 06:51:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities ...

2024-02-09 06:25:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longe...